AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma - LARVOL DELTA

Interim analysis of adebrelimab plus famitinib as later-line treatment for extensive-stage small cell lung cancer: A phase II clinical trial (ESMO Asia 2025) - P=N/A | "Adebrelimab combined with famitinib showed promising survival benefits with manageable toxicity in relapsed ES-SCLC, particularly in heavily pretreated pts and those with prior immunotherapy exposure."

Clinical • P2 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Clinical outcomes and safety of continuous immunotherapy and anti-angiogenic combination therapy beyond progression in patients with extensive-stage small cell lung cancer: A retrospective real-world study (ESMO Asia 2025) - "This multi-center retrospective study aimed to investigate the efficacy of continuous immunotherapy (I) and addition of anti-angiogenic agent (A) in relapsed ES-SCLC. We retrospectively reviewed the medical records of ES-SCLC patients treated with first-line I+C therapy in three medical centers in Shandong Province. From Jan 2020 to Dec 2024, 354 patients were enrolled and 241 (68.1%) received PD-L1 antibody including atezolizumab, durvalumab, adebrelimab, while 113 (31.9%) received PD-1 antibody such as serplulimab. Continuous immunotherapy beyond progression in ES-SCLC demonstrates a trend toward prolonged second-line PFS, but does not improve the overall survival. In the second-line treatment, chemotherapy remains an indispensable cornerstone."

Clinical data • Combination therapy • Real-world • Real-world evidence • Retrospective data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Hepatic arterial infusion chemotherapy combined with adebrelimab and lenvatinib for conversion treatment of potentially resectable, locally advanced biliary tract cancers: A single-arm, exploratory clinical study (ESMO Asia 2025) - P2 | "HAIC consisted of infusions of gemcitabine (1000 mg for 2 hours) and cisplatin (37.5 mg/m2 for two doses, 24 hours apart, 2 hours each time)± 5-FU (1250 mg/m2 for 48 hours) on day1-3 every 3 weeks...The primary endpoints are R0 resection rate and surgical conversion rate, secondary endpoints include pathologic complete remission, major pathological response, recurrence-free survival, overall survival, patient-reported outcome and safety. An analysis of biomarkers will be performed to predict response or resistance to the treatment."

Clinical • IO biomarker • Metastases • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor • PD-L1

Adebrelimab combined with Celecoxib and chemotherapy as first-line treatment for PD-L1-positive and HER2-negative locally advanced gastric/gastroesophageal junction adenocarcinoma: A single-arm, exploratory clinical trial (ESMO Asia 2025) - P4 | "Eligible patients will receive a combination of adebrelimab, celecoxib, and either XELOX or SOX, administered once every 21-day cycle, and continued until disease progression, unacceptable toxicity, withdrawal of informed consent, or investigator-determined study termination. The secondary endpoints include disease control rate, duration of response, progression-free survival, overall survival, and safety. Exploratory endpoints included the correlation between COX-2 expression and treatment efficacy and prognosis, as well as the association of cytokines IL-6, IL-8, and IL-10 with efficacy and prognosis."

Clinical • IO biomarker • Metastases • Esophageal Cancer • Gastric Adenocarcinoma • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • CXCL8 • HER-2 • IL10 • IL6 • PTGS2

Neoadjuvant Adebrelimab plus SOX and Nab-paclitaxel in Resectable locally advanced gastric and gastroesophageal junction adenocarcinoma: A multicentre, single-arm, prospective phase II trial (ESMO Asia 2025) - P2, P3 | "Background: Perioperative chemotherapy containing fluorouracil, oxaliplatin, and docetaxel is preferred for patients with gastric and gastroesophageal junction adenocarcinoma. The KEYNOTE-585 study reported that the neoadjuvant and adjuvant pembrolizumab plus cisplatin-based chemotherapy group achieved a higher pathological complete response rate than the placebo plus cisplatin-based chemotherapy group...The primary endpoint is the pathological complete response rate. Secondary research endpoints include: major pathologic response, objective response rate, R0 resection rate, disease-free survival, overall survival, and safety."

Clinical • Metastases • P2 data • Esophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Phase II study of adebrelimab combined with apatinib and nab-paclitaxel as second-line therapy in patients with advanced gastric cancer previously treated with immunotherapy (ESMO Asia 2025) - P2 | "The combination of Adebrelimab, Apatinib, and nab-Paclitaxel demonstrated modest efficacy and manageable safety as second-line treatment of advanced gastric cancer, representing a potential new option. Further randomized controlled trials are warranted to confirm the long-term efficacy and safety of this regimen."

Clinical • Metastases • P2 data • Gastric Cancer • Oncology • Solid Tumor

Efficacy and safety of adebrelimab combined with S-1 plus oxaliplatin in neoadjuvant therapy for locally advanced gastric adenocarcinoma (ESMO Asia 2025) - P4 | "Adebrelimab plus SOX demonstrates superior pathological responses versus chemotherapy alone, establishing a promising neoadjuvant regimen for locally advanced gastric adenocarcinoma. Although associated with increased immune-related toxicity, the safety profile remains acceptable."

Clinical • Metastases • Gastric Adenocarcinoma • Oncology • Solid Tumor

Adebrelimab combined with albumin-paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced resectable esophageal squamous cell carcinoma: A multicenter, single-arm, phase II clinical study. (ASCO-GI 2026) - P2 | "Clinical Trial Registration Number: NCT06508229 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Metastases • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Cancer • Oncology

Neoadjuvant adebrelimab plus SOX and nab-paclitaxel in resectable locally advanced gastric and gastroesophageal junction adenocarcinoma: A multicentre, single-arm, prospective phase II trial. (ASCO-GI 2026) - P2 | "Clinical Trial Registration Number: ChiCTR2400082697 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Metastases • P2 data • Esophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

Adebrelimab with or without induction chemotherapy followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (RICE): A prospective, phase 2 trial. (ASCO-GI 2026) - P2 | "Clinical Trial Registration Number: NCT06510660 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Metastases • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Cancer • Oncology

Comment on "Neoadjuvant immunochemotherapy with adebrelimab combined with the TP regimen for locally advanced OSCC". (PubMed, Int J Surg) - No abstract available

Journal • Oral Cancer

First line PD-L1/1 inhibition based therapies in elderly patients with ES-SCLC: a Systematic Literature Review and Network Meta-Analysis (ESMO-IO 2025) - "Currently, PD-1/PD-L1 inhibitors with platinum and etoposide (EP) have been adopted as standard first-line therapy and idemonstrated survival benefits in the overall population, while the magnitude of benefit and optimal agent in elderly patients remain unclear.Methods Following PRISMA-NMA guidelines, PubMed and ClinicalTrials.gov were searched up to 29 August 2025. Eligible RCTs compared first-line PD-L1 or PD-1 inhibitors—atezolizumab, durvalumab, serplulimab, adebrelimab, tislelizumab, pembrolizumab, socazolimab, benmelstobart(+anlotinib), nivolumab, or toripalimab with or without EP in ES-SCLC...Atezolizumab-EP ranked highest for OS (SUCRA=0.88), followed by Benmelstobart + anlotinib -EP (SUCRA = 0.86) and serplulimab-EP (SUCRA = 0.77), whereas durvalumab-EP (SUCRA = 0.36) and socazolimab-EP (SUCRA = 0.29) showed relatively modest effects.Conclusions First-line PD-L1/PD-1 inhibition plus EP confers a clinically meaningful survival advantage in elderly patients with..."

Retrospective data • Review • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC) (clinicaltrials.gov) - P3 | N=604 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

New P3 trial • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

SHR-A2102-212: A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=300 | Recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

RJBLC-NEBC001: Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma (clinicaltrials.gov) - P2 | N=22 | Recruiting | Sponsor: RenJi Hospital | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: Jan 2026 ➔ Jan 2027

Trial completion date • Trial primary completion date • Bladder Cancer • Endocrine Cancer • Genito-urinary Cancer • Genitourinary Neuroendocrine Carcinoma • Neuroendocrine Carcinoma • Oncology • Solid Tumor

Comment on "Neoadjuvant immunochemotherapy with adebrelimab combined with the TP regimen for locally advanced OSCC: early results of a single-arm phase II clinical trial". (PubMed, Int J Surg) - No abstract available

Journal • P2 data • Oral Cancer

Adebrelimab in the adjuvant treatment of esophageal squamous cell carcinoma: A randomized controlled clinical trial (PAIT-ESCC-0825) (ESMO-IO 2025) - "In adjuvant therapy for esophageal cancer patients who did not achieve pCR after neoadjuvant chemoradiotherapy, nivolumab is the standard treatment regimen. The stratification factor was postoperative pathological response to pCR (yes vs. no) and ever received immunotherapy (yes or no). Study Endpoints: Primary endpoint: Disease-Free Survival (DFS) & Secondary endpoints: Overall survival (OS), patient reported outcomes (PRO) and safety.Clinical trial identification PAIT-ESCC-0825.Legal entity responsible for the study The Fourth Hospital of Hebei Medical University."

Clinical • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

ACPC: Adebrelimab and Chidamide for Pancreatic Cancer (clinicaltrials.gov) - P2 | N=45 | Recruiting | Sponsor: Liu Xiufeng | Not yet recruiting ➔ Recruiting | N=77 ➔ 45 | Trial completion date: Jul 2026 ➔ May 2027 | Trial primary completion date: Jul 2025 ➔ Jul 2026

Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Oncology • Pancreatic Cancer • Solid Tumor

Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom (clinicaltrials.gov) - P1/2 | N=139 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

New P1/2 trial • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - P3 | N=460 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

CATALIS: Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study (clinicaltrials.gov) - P2 | N=30 | Not yet recruiting | Sponsor: Shanghai Zhongshan Hospital

dMMR • Mismatch repair • MSI-H • New P2 trial • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Microsatellite Instability • Oncology • Solid Tumor

Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma. (clinicaltrials.gov) - P2 | N=142 | Recruiting | Sponsor: Hebei Medical University Fourth Hospital

New P2 trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors (clinicaltrials.gov) - P2 | N=400 | Not yet recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

New P2 trial • Oncology • Solid Tumor

Trop2-directed antibody-drug conjugate shr-a1921 combined with pd-l1 inhibitor adebrelimab for patients with advanced triple negative breast cancer: results from a phase 2, multi-cohort, open-label, non-controlled trial (SABCS 2025) - P2 | "The combination of SHR-A1921 and adebrelimab demonstrated promising anti-tumor efficacy and manageable safety in pretreated TNBC pts regardless of PD-L1 status, warranting further investigations in this population. Our exploration of ADCs combined with adebrelimab in HER2-negative advanced breast cancer is still ongoing."

Clinical • Metastases • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2

Precision neoadjuvant treatment with Artificial Intelligence assisted subtyping in HR+/HER2- breast cancer: a randomized, open-label, phase 2 trial FASCINATE-N (SABCS 2025) - P2 | "Precision treatments included six cycles of dalpicilib (CDK4/6 inhibitor) plus endocrine therapy every 4 weeks for endocrine-based group and six cycles of targeted therapy (SHR-1316 [PD-L1 inhibitor] for SNF2, fuzuloparib [PARP1 inhibitor] for SNF3 and apatinib [VEGFR inhibitor] for SNF4) plus nab-paclitaxel and carboplatin every 4 weeks for targeted-based group. NET plus CDK4/6 inhibitor was verified to replace chemotherapy with better tolerance in the endocrine-base group while precision therapy was proved promising clinical activity and manageable safety profile in the targeted-based group. (ClinicalTrials.gov: NCT05582499)."

Clinical • IO biomarker • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • SMARCA2